𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

✍ Scribed by M. Kuoppamäki; G. Al-Barghouthy; M. J. Jackson; L. A. Smith; N. Quinn; P. Jenner

Publisher
Springer
Year
2007
Tongue
English
Weight
248 KB
Volume
114
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

De novo administration of ropinirole and
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
✍ Ronald K. B. Pearce; Tara Banerji; Professor Peter Jenner; C. David Marsden 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 760 KB

## Abstract In contrast to levodopa (L‐dopa), de novo administration of the D2‐like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated subhuman primates is not associated with the onset of significant dyskinesia

Repeated administration of piribedil ind
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation
✍ Lance A. Smith; Banu C. Tel; Michael J. Jackson; Matthew J. Hansard; Rogelio Bra 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 615 KB

## Abstract Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D~2~/D~3~ dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal g

Multiple small doses of levodopa plus en
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naïve primates
✍ Lance A. Smith; Michael J. Jackson; Ghassan Al-Barghouthy; Sarah Rose; Mikko Kuo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

## Abstract Long‐acting dopamine agonist drugs induce a lower incidence of dyskinesia in MPTP‐treated primates and patients with Parkinson's disease compared to pulsatile treatment with levodopa, supporting the concept of continuous dopaminergic stimulation as a means of dyskinesia avoidance. We ex